Lipid Clinics Network. Rationale and design of the EAS global project

被引:9
作者
Alieva, Asiiat S. [1 ]
Tokgozoglu, Lale [2 ]
Ray, Kausik K. [3 ]
Catapano, Alberico L. [4 ]
机构
[1] Almazov Natl Med Res Ctr, Ctr Atherosclerosis & Lipid Disorders, St Petersburg, Russia
[2] Hacettepe Univ, Dept Cardiol, Ankara, Turkey
[3] Imperial Coll, Dept Primary Care & Publ Hlth, Imperial Ctr Cardiovasc Dis Prevent, London, England
[4] Univ Milan, Dept Pharmacol & Biomol Sci, Multimed IRCCS, Milan, Italy
关键词
Cardiovascular risk; Dyslipidemia; Risk management; European guidelines;
D O I
10.1016/j.atherosclerosissup.2021.01.002
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The evidence of the causal role of low-density lipoprotein cholesterol in the development of atherosclerotic cardiovascular disease is well-established. The clearly identified common position of the European guidelines proclaims necessity to decrease LDL-C concentrations based on a proper risk stratification. However, current worldwide situation with the lipid management still demonstrates inadequate dyslipidemia control, that is probably related to a healthcare system issues. As the need to standardize and implement approaches following the guidelines into clinical practice remains a challenge, the EAS initiates the Lipid Clinics Network project, aiming to provide a structure to establish uniform EU-wide standards of diagnosis, management and treatment of patients with lipid disorders, based on the ESC/EAS Guidelines on management of dyslipidaemias. (c) 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:E6 / E8
页数:3
相关论文
共 5 条
[1]   Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel [J].
Ference, Brian A. ;
Ginsberg, Henry N. ;
Graham, Ian ;
Ray, Kausik K. ;
Packard, Chris J. ;
Bruckert, Eric ;
Hegele, Robert A. ;
Krauss, Ronald M. ;
Raal, Frederick J. ;
Schunkert, Heribert ;
Watts, Gerald F. ;
Boren, Jan ;
Fazio, Sergio ;
Horton, Jay D. ;
Masana, Luis ;
Nicholls, Stephen J. ;
Nordestgaard, Borge G. ;
van de Sluis, Bart ;
Taskinen, Marja-Riitta ;
Tokgozoglu, Lale ;
Landmesser, Ulf ;
Laufs, Ulrich ;
Wiklund, Olov ;
Stock, Jane K. ;
Chapman, M. John ;
Catapano, Alberico L. .
EUROPEAN HEART JOURNAL, 2017, 38 (32) :2459-2472
[2]   Prediction of individualized lifetime benefit from cholesterol lowerirg, blood pressure lowering, antithrombotic therapy, and smokirg cessation in apparently healthy people [J].
Jaspers, Nicole E. M. ;
Blaha, Michael J. ;
Matsushita, Kunihiro ;
van der Schouw, Yvonne T. ;
Wareham, Nicholas J. ;
Khaw, Kay-Tee ;
Geisel, Marie H. ;
Lehmann, Nils ;
Erbel, Raimund ;
Joeckel, Karl-Heinz ;
van der Graaf, Yolanda ;
Verschuren, W. M. Monique ;
Boer, Jolanda M. A. ;
Nambi, Vijay ;
Visseren, Frank L. J. ;
Dorresteijn, Jannick A. N. .
EUROPEAN HEART JOURNAL, 2020, 41 (11) :1190-1199
[3]   EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study [J].
Ray, Kausik K. ;
Molemans, Bart ;
Schoonen, W. Marieke ;
Giovas, Periklis ;
Bray, Sarah ;
Kiru, Gaia ;
Murphy, Jennifer ;
Banach, Maciej ;
De Servi, Stefano ;
Gaita, Dan ;
Gouni-Berthold, Ioanna ;
Hovingh, G. Kees ;
Jozwiak, Jacek J. ;
Jukema, J. Wouter ;
Kiss, Robert Gabor ;
Kownator, Serge ;
Iversen, Helle K. ;
Maher, Vincent ;
Masana, Luis ;
Parkhomenko, Alexander ;
Peeters, Andre ;
Clifford, Piers ;
Raslova, Katarina ;
Siostrzonek, Peter ;
Romeo, Stefano ;
Tousoulis, Dimitrios ;
Vlachopoulos, Charalambos ;
Vrablik, Michal ;
Catapano, Alberico L. ;
Poulter, Neil R. .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (11) :1279-1289
[4]   The year in cardiology: cardiovascular prevention The year in cardiology 2019 [J].
Ray, Kausik K. ;
Laufs, Ulrich ;
Cosentino, Francesco ;
Lobo, Melvin D. ;
Landmesser, Ulf .
EUROPEAN HEART JOURNAL, 2020, 41 (11) :1157-+
[5]  
Rose G, 1992, STRATEGY PREVENTIVE, P171